1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin 58(2):71-96, 2008.
2. Heintz AP, Odicino F, Maisonneuve P, et al: Carcinoma of the ovary. Int J Gynaecol Obstet 83(Suppl 1):135-166, 2003.
3. Levine DA, Argenta PA, Yee CJ, et al: Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J Clin Oncol 21(22):4222-4227, 2003.
4. Rodriguez GC, Walmer DK, Cline M, et al: Effect of progestin on the ovarian epithelium of macaques: cancer prevention through apoptosis? J Soc Gynecol Invest 5(5):271-276, 1998.
5. Hankinson SE, Colditz GA, Hunter DJ, et al: A quantitative assessment of oral contraceptive use and risk of ovarian cancer. Obstet Gynecol 80(4):708-714, 1992.
6. Whittemore AS, Harris R, Itnyre J: Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 136(10):1184-1203, 1992.
7. The reduction in risk of ovarian cancer associated with oral-contraceptive use. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. N Engl J Med 316(11):650-655, 1987.
8. Ness RB, Grisso JA, Klapper J, et al: Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. SHARE Study Group. Steroid Hormones and Reproductions. Am J Epidemiol 152(3):233-241, 2000.
9. Schildkraut JM, Calingaert B, Marchbanks PA, et al: Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J Natl Cancer Inst 94(1):32-38, 2002.
10. John EM, Whittemore AS, Harris R, Itnyre J: Characteristics relating to ovarian cancer risk: collaborative analysis of seven U.S. case-control studies. Epithelial ovarian cancer in black women. Collaborative Ovarian Cancer Group. J Natl Cancer Inst 85(2):142-147, 1993.
11. La Vecchia C, Franceschi S: Oral contraceptives and ovarian cancer. Eur J Cancer Prev 8(4):297-304, 1999.
12. Rosenberg L, Palmer JR, Zauber AG, et al: A case-control study of oral contraceptive use and invasive epithelial ovarian cancer. Am J Epidemiol 139(7):654-661, 1994.
13. Stanford JL: Oral contraceptives and neoplasia of the ovary. Contraception 43(6):543-556, 1991.
14. Bosetti C, Negri E, Trichopoulos D, et al: Long-term effects of oral contraceptives on ovarian cancer risk. Int J Cancer 102(3):262-265, 2002.
15. Narod SA, Risch H, Moslehi R, et al: Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 339(7):424-428, 1998.
16. Modan B, Hartge P, Hirsh-Yechezkel G, et al: Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 345(4):235-240, 2001.
17. Whittemore AS, Balise RR, Pharoah PD, et al: Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations. Br J Cancer 91(11):1911-1915, 2004.
18. Walker GR, Schlesselman JJ, Ness RB: Family history of cancer, oral contraceptive use, and ovarian cancer risk. Am J Obstet Gynecol 186(1):8-14, 2002.
19. Averette HE, Nguyen HN: The role of prophylactic oophorec-tomy in cancer prevention. Gynecol Oncol 55(3 Pt 2):S38-S41, 1994.
20. Hankinson SE, Hunter DJ, Colditz GA, et al: Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study. JAMA 270(23):2813-2818, 1993.
21. Finch A, Shaw P, Rosen B, et al: Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol 100(1):58-64, 2006.
22. Powell CB: Occult ovarian cancer at the time of risk-reducing salpingo-oophorectomy. Gynecol Oncol 100(1):1-2, 2006.
23. Kauff ND, Barakat RR: Surgical risk-reduction in carriers of BRCA mutations: where do we go from here? Gynecol Oncol 93(2):277-279, 2004.
24. Rebbeck TR, Lynch HT, Neuhausen SL, et al: Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346(21):1616-1622, 2002.
25. Kauff ND, Satagopan JM, Robson ME, et al: Risk-reducing sal-pingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346(21):1609-1615, 2002.
26. Rutter JL, Wacholder S, Chetrit A, et al: Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study. J Natl Cancer Inst 95(14):1072-1078,
27. Olivier RI, van Beurden M, Lubsen MA, et al: Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up. Br J Cancer 90(8):1492-1497,
28. Parazzini F, La Vecchia C, Negri E: Oral contraceptive use and the risk of ovarian cancer: an Italian case-control study. Eur J
Cancer 27(5):594-598, 1991.
Was this article helpful?
Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.